Predictive models and clinical manifestations of intrapulmonary vascular dilatation and hepatopulmonary syndrome in patients with cirrhosis: Prospective comparative study

Figure 3 Receiver operating characteristic curves for predicting intrapulmonary vascular dilatation and hepatopulmonary syndrome by different parameters. A: Predicting intrapulmonary vascular dilatation (IPVD) in patients with cirrhosis. Area under the curve (AUC) for: Age was 0.613 (95% confidence interval [CI]: 0.546-0.679), Model for End-Stage Liver Disease (MELD) (score) 0.691 (95%CI: 0.629-0.753), arterial oxygen pressure 0.565 (95%CI: 0.496-0.633), reticulocalbin 3 0.587 (95%CI: 0.518-0.656), sphingosine 1 phosphate (S1P) 0.649 (95%CI: 0.584-0.714), angiopoietin-2 0.699 (95%CI: 0.638-0.760), and platelet-derived growth factor BB (PDGF-BB) 0.647 (95%CI: 0.583-0.711); B: Predicting hepatopulmonary syndrome (HPS) in patients with cirrhosis. AUC for age was 0.618 (95%CI: 0.542-0.693), pulmonary alveolar-arterial oxygen gradient (P(A-a)O₂) 0.837 (95%CI: 0.790-0.885), hemoglobin (HGB) 0.674 (95%CI: 0.600-0.749), total bilirubin (TBIL) 0.749 (95%CI: 0.681-0.818), albumin (ALB) 0.734 (95%CI: 0.667-0.801), S1P 0.635 (95%CI: 0.556-0.713); angiopoietin-2 0.726 (95%CI: 0.652-0.800), and PDGF-BB 0.599 (95%CI: 0.519-0.679). FPR: False-positive rate; TPR: True-positive rat.